Stock listing

OTC:ANEB Anebulo Pharmaceuticals, Inc. Stock

Home listing (OTC) of Anebulo Pharmaceuticals, Inc.

Follow Anebulo Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · OTC:ANEB

$0.26 USD -0.02 (-7.1%)

Close on Nov 20, 2026

Past year -88.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.26 – $0.26 USDNov 20, 2026
Volume
100 sharesNov 20, 2026
Market cap
$10.60M USDAt the close on Nov 20, 2026 · price × 40.78M shares outstanding
52-week range
$0.0010 – $2.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$118 USDMedian day 100 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Anebulo Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:ANEB · Home$0.26 USD-0.02 (-7.1%)100$0.26$0.26$0.26$0.28Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ANEB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.26-0.02-7.1%$0.26$0.26$0.26100
$0.280.000.0%$0.28$0.28$0.28100
$0.28+0.02+7.7%$0.28$0.28$0.28100
$0.26-0.02-7.1%$0.26$0.26$0.26106
$0.28+0.02+7.7%$0.28$0.28$0.28100
$0.26-0.003-1.0%$0.26$0.26$0.26100
$0.263-0.027-9.4%$0.263$0.263$0.263100
$0.29+0.015+5.5%$0.29$0.29$0.29103
$0.275+0.015+5.8%$0.275$0.275$0.275100
$0.260.000.0%$0.26$0.26$0.001018,400
$0.260.000.0%$0.26$0.26$0.26100
$0.260.000.0%$0.26$0.26$0.26100
$0.26+0.018+7.5%$0.26$0.26$0.26100
$0.242-0.018-7.0%$0.242$0.242$0.242123
$0.26-0.015-5.5%$0.26$0.26$0.26100
$0.275+0.015+5.8%$0.275$0.275$0.275100
$0.26-0.015-5.5%$0.26$0.26$0.26100
$0.275-0.015-5.2%$0.275$0.275$0.275100
$0.290.000.0%$0.29$0.29$0.29100
$0.290.000.0%$0.29$0.29$0.29100
$0.29-0.005-1.7%$0.29$0.29$0.29100
$0.295-0.015-4.8%$0.295$0.295$0.295100
$0.310.000.0%$0.31$0.31$0.31100
$0.31-0.005-1.6%$0.31$0.31$0.31100
$0.3150.000.0%$0.315$0.315$0.315100
$0.3150.000.0%$0.315$0.315$0.315100
$0.315+0.005+1.6%$0.315$0.315$0.315100
$0.31-0.01-3.1%$0.31$0.31$0.31100
$0.320.000.0%$0.32$0.32$0.32100
$0.320.000.0%$0.32$0.32$0.32102
$0.320.000.0%$0.32$0.32$0.32113
$0.320.000.0%$0.32$0.32$0.32100
$0.320.000.0%$0.32$0.32$0.32106
$0.320.000.0%$0.32$0.32$0.32100
$0.320.000.0%$0.32$0.32$0.32100
$0.32-0.005-1.5%$0.32$0.32$0.32100
$0.3250.000.0%$0.30$0.325$0.30374
$0.325+0.025+8.3%$0.325$0.325$0.325200
$0.30-0.015-4.8%$0.30$0.30$0.302,200
$0.3150.000.0%$0.315$0.315$0.3150
$0.315+0.015+5.0%$0.315$0.315$0.315114
$0.30-0.034-10.2%$0.30$0.30$0.30100
$0.334-0.026-7.2%$0.334$0.334$0.334100
$0.360.000.0%$0.36$0.36$0.36100
$0.36+0.028+8.6%$0.011$0.36$0.011200
$0.3320.000.0%$0.332$0.332$0.332100
$0.3320.000.0%$0.332$0.332$0.332100
$0.332-0.026-7.2%$0.332$0.332$0.332100
$0.357-0.033-8.4%$0.357$0.357$0.357100
$0.39+0.031+8.6%$0.39$0.39$0.39100
$0.359-0.031-7.9%$0.359$0.359$0.359100
$0.39+0.09+30.0%$0.39$0.39$0.39100
$0.30-0.015-4.8%$0.30$0.30$0.30100
$0.3150.000.0%$0.315$0.315$0.3150
$0.3150.000.0%$0.315$0.315$0.3150
$0.315-0.015-4.5%$0.315$0.315$0.315100
$0.330.000.0%$0.33$0.33$0.33100
$0.330.000.0%$0.33$0.33$0.33100
$0.33+0.017+5.4%$0.33$0.33$0.33100
$0.313-0.017-5.2%$0.313$0.313$0.313100
$0.33-0.02-5.7%$0.33$0.33$0.33100
$0.350.000.0%$0.35$0.35$0.350
Ticker
OTC:ANEB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Anebulo Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Decks
5 decks · latest October 2024

Where Anebulo Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
OTC:ANEB · Home listing · This pageOTCUnited StatesUSD
LS Exchange:A3CM1DLS ExchangeGermanyEUR

Valuation

Price/book 1.3× against a median of 1.1×: 6th lowest of 8 Biotechnology companies shown. Statements: Year to Jun 30, 2025 · balance Dec 31, 2025 · price Nov 20, 2026

Enterprise value
$1.56M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
-0.01

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Anebulo Pharmaceuticals, Inc. · OTC:ANEBUS$10.60MUS$1.56Mn/an/an/a1.3×n/a0.0×-0.01
Dyadic International, Inc. · NASDAQ:DYAIUS$11.51MUS$12.03Mn/a3.9×n/an/a−226.9%n/a1.12
Psyence Biomedical Ltd. · NASDAQ:PBMUS$11.33MUS$4.18Mn/an/an/a0.9×n/a0.0×0.90
Medicenna Therapeutics Corp. · TSX:MDNAUS$11.26MUS$7.37Mn/an/an/a9.7×n/a0.1×1.36
Miro Sciences Ltd · ASX:MSXUS$11.09MUS$8.03Mn/an/an/a1.1×n/a0.0×n/a
Shaperon Inc. · KRX:378800US$11.05M−US$8.11Mn/a−33.9×n/a0.8×n/a0.0×n/a
Fractyl Health, Inc. · NASDAQ:GUTSUS$10.88M−US$20.64Mn/an/an/an/an/an/a1.78
TME Pharma N.V. · EURONEXT:ALTMEUS$10.76MUS$12.80Mn/an/an/an/an/an/an/a
PharmAla Biotech Holdings, Inc. · CSE:MDMAUS$10.76MUS$10.59Mn/a12.0×n/a7.9×−126.9%0.0×0.38
IRLAB Therapeutics AB Class A · OMXSTO:IRLAB_AUS$10.60MUS$9.62Mn/a1.2×n/a1.1×−67.9%0.3×n/a
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
Median of the othersUS$10.96MUS$7.70M0.1×1.2×1.1×−126.9%0.0×1.12

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
3.00 USD · Analysts' mean
EPS, year to Jun 2026
-0.48 · 1 analyst

Team and board

Officers

OfficerRole
Richie CunninghamChief Executive Officer
Daniel GeorgeActing Chief Financial Officer
Kenneth CundyChief Scientific Officer

Board

DirectorRole
Joseph F. LawlerChairman
Areta KupchykBoard Member
Aron EnglishBoard Member
Jason AryehBoard Member
Kenneth LinBoard Member
Nat CallowayBoard Member
Richie CunninghamChief Executive Officer

Events

QuarterResultsShare move
Quarter to Mar 31, 2026May 7, 2026+6.4%
Q2 2026Feb 12, 2026+0.9%
Q1 2026Nov 13, 2025 · After close−3.8%
Q4 2025Sep 29, 2025+4.2%
Q3 2025May 13, 2025 · After close+0.5%
Q2 2025Feb 14, 2025 · After close+9.8%
Q1 2025Nov 13, 2024 · After close−1.9%
Q4 2024Sep 25, 2024 · After close+6.0%
Q3 2024May 15, 2024 · After close−6.4%
Q2 2024Feb 13, 2024 · After close+5.4%
All 20 quarters
QuarterResultsShare move
Q1 2024Nov 14, 2023 · After close+5.2%
Q4 2023Sep 20, 2023 · After close−0.3%
Q3 2023May 11, 2023 · After close0.0%
Q2 2023Feb 10, 2023 · Before open+3.8%
Q1 2023Nov 10, 2022 · Before open−2.8%
Q4 2022Sep 9, 2022 · Before open−3.5%
Q3 2022May 11, 2022 · After close−2.9%
Q2 2022Feb 10, 2022 · After close−1.3%
Q1 2022Nov 12, 2021 · Before open−2.0%
Q4 2021Sep 22, 2021 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2024)Investor deck21 slidesOctober 2024
Investor Presentation (January 2023)Investor deck33 slidesJan 9, 2023
Investor Day (September 2022)Investor day53 slidesSep 26, 2022
Technical Presentation (July 2022)Technical14 slidesJul 5, 2022
IPO Roadshow (April 2021)IPO roadshow26 slidesApr 26, 2021

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue00000
Research and development4.30M3.55M5.60M2.96M2.27M150.0K
Selling, general and administrative4.92M4.75M6.18M3.87M1.34M140.1K
Operating income-9.22M-8.31M-11.8M-6.83M-3.61M-173.4K
Depreciation and amortization382.0K151.2K11.8K6.83M3.61M1.04M
EBITDA-8.84M-8.16M-11.8M-1740866.8K
Interest expense400.0K200.0K07.33K11.8K1.29K
Income before tax-8.48M-8.20M-11.7M-6.83M-3.61M-174.6K
Income tax-104.2K-12.9K10.7K-1.04K
Net income-8.48M-8.20M-11.7M-6.83M-30.3M-174.6K
Earnings per share, basic-0.25-0.32-0.470.29-2.83-0.01
Earnings per share, diluted-0.25-0.32-0.470.29-2.83

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents11.6M3.09M11.2M14.5M20.0M3.02M
Receivables73.2K3.50K
Inventory-4
Current assets12.0M3.51M11.7M15.6M21.7M3.03M
Total assets12.1M4.07M11.7M15.6M21.7M3.03M
Accounts payable224.2K156.4K534.5K380.8K110.0K0
Current liabilities224.2K260.6K1.07M512.5K241.6K223.9K
Total debt201.3K
Total liabilities487.7K260.6K1.07M512.5K241.6K223.9K
Shareholders' equity11.7M3.81M10.6M15.1M21.4M2.80M
Shares outstanding41.1M25.9M25.6M23.3M23.3M23.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-6.35M-8.09M-9.68M-5.44M-4.87M-150.8K
Capital spending-3-10-40-2
Free cash flow-6.35M-8.09M-9.68M-5.44M-4.87M-150.8K
Cash from financing14.9M-62.4K6.38M6.38M21.8M3.18M
Dividends paid-8.21M
Share buybacks8.21M3.00M
Change in cash8.53M-8.15M-3.30M-5.44M17.0M3.02M

Open Financials

Cap table

Built by 6ix from Anebulo Pharmaceuticals, Inc.’s releases

Common shares
40,784,731
Fully diluted
40,784,731

Fully diluted

LineShares
Common shares40,784,731

Share count over time

CountShares
Nov 22, 202640,784,731

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jason M. Aryeh
Other companies: Lifecore Biomedical, Inc. (Director · Since at least Aug 15, 2024); Orchestra BioMed Holdings, Inc. (Director · Since at least Jan 26, 2023); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Myrexis Inc (Director · Oct 19, 2011 – Jun 18, 2012 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past)
Board Member · Since at least May 6, 2021
Sandra A Gardiner
Other companies: Adagio Medical Holdings, Inc (Director · Since at least Jul 31, 2024); Kronos Bio Inc (Interim CFO · Sep 15, 2023 – Sep 15, 2023 · Past); Nektar Therapeutics (Chief Financial Officer · Apr 17, 2023 – Apr 17, 2023 · Past); Lucira Health Inc (Director · Feb 4, 2021 – Jun 1, 2022 · Past); Pulse Biosciences, Inc (CFO & EVP Admin. and Finance · Dec 9, 2020 – Dec 14, 2021 · Past)
Acting Chief Financial Officer · Mar 2, 2023 – Mar 2, 2023 · Past
Aron R. English
Other companies: Stoneridge, Inc. (Director · Since at least Feb 26, 2026); Dirtt Environmental Solutions Ltd (Director · Since at least Jun 30, 2022)
Board Member · Since at least May 6, 2021
Daniel George
Other companies: Adagio Medical Holdings, Inc (Interim CFO · Apr 17, 2025 – Apr 17, 2025 · Past)
Acting Chief Financial Officer · Since at least Nov 5, 2026
Richard Anthony Cunningham
Other companies: Tyme Technologies Inc (Chief Executive Officer · Apr 25, 2022 – Sep 16, 2022 · Past)
Chief Executive Officer, Director · Oct 6, 2023 – Apr 4, 2025 · Past
Areta KupchykBoard Member · Since at least May 6, 2021
Bimal ShahSince at least Nov 5, 2026
Joseph F. LawlerChairman · Since at least Nov 5, 2026
Kenneth CundyChief Scientific Officer · Since at least Apr 4, 2025
Kenneth LinBoard Member · Since at least Nov 5, 2026
All 13 people
PersonSeat
Nat CallowayBoard Member · Since at least Nov 5, 2026
Richie CunninghamChief Executive Officer · Since at least Nov 5, 2026
Simon AllenChief Executive Officer, Director · Feb 1, 2022 – Dec 9, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Anebulo Pharmaceuticals, Inc.